1
|
Tall ML, Diouf E, Filali S, Sauvinet V, Laleye D, Dhelens C, Salmon D, Gabert L, Nugue G, Sandre-Balester C, Berger F, Pirot F, Pivot C. [Injectable hospital preparation of valine labeled with the carbon 13 and nitrogen 15 (5 mg/mL) for a clinical trial on the brain tumor metabolism: Pharmaceutical control of active pharmaceutical ingredient and stability study of the finished product]. ANNALES PHARMACEUTIQUES FRANÇAISES 2015; 73:361-77. [PMID: 25747724 DOI: 10.1016/j.pharma.2015.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Revised: 01/28/2015] [Accepted: 02/02/2015] [Indexed: 10/23/2022]
Abstract
INTRODUCTION The L-Valine labeled (L-[U-(13)C,(15)N] Val) is a stable isotopic tracer administered by parenteral route within the framework of a new clinical research program concerning the brain tumor metabolism. To meet regulatory requirements and have ready to use solution with an expiration date, a pharmaceutical control of active pharmaceutical ingredient followed by stability study of hospital preparation were realised. MATERIALS AND METHODS After the pharmaceutical control of the L-[U-(13)C,(15)N] Val, the hospital preparation was prepared according to the good manufacturing preparation. Prepared bottles were stored at 5°C±3°C and 25°C±2°C for six months. The stability of the preparation was determined by physico-chemical controls (pH, osmolality, sub-visible particles, L-[U-(13)C,(15)N] Val concentration, sodium concentration, isotopic enrichment) and microbiological (bacterial endotoxin and sterility). RESULTS Concentrations of L-[U-(13)C, (15)N] Val and sodium does not significantly decrease during the stability study. In parallel, no change in pH and osmolality were highlighted. Isotopic enrichment higher than 99.9% reflected the stability of labeling of L-valine molecule. The sub-visible particles, the bacterial endotoxin and sterility were in accordance with the European Pharmacopoeia attesting limpidity, apyrogenicity and sterility of this injectable preparation. DISCUSSION AND CONCLUSION The stability of this hospital preparation of L-[U-(13)C, (15)N] Val has been demonstrated for six months at 5°C±3°C and 25°C±2°C, ensuring a parenteral administration as part of the clinical trial.
Collapse
Affiliation(s)
- M L Tall
- Pharmacie, groupement hospitalier Édouard-Herriot, plateforme Fripharm, 5, place d'Arsonval, 69437 Lyon cedex 03, France.
| | - E Diouf
- Pharmacie, groupement hospitalier Édouard-Herriot, plateforme Fripharm, 5, place d'Arsonval, 69437 Lyon cedex 03, France
| | - S Filali
- Pharmacie, groupement hospitalier Édouard-Herriot, plateforme Fripharm, 5, place d'Arsonval, 69437 Lyon cedex 03, France
| | - V Sauvinet
- Centre de recherche en nutrition humaine, Rhône Alpes, centre européen nutrition santé, groupement hospitalier Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France
| | - D Laleye
- Pharmacie, groupement hospitalier Édouard-Herriot, plateforme Fripharm, 5, place d'Arsonval, 69437 Lyon cedex 03, France
| | - C Dhelens
- Pharmacie, groupement hospitalier Édouard-Herriot, plateforme Fripharm, 5, place d'Arsonval, 69437 Lyon cedex 03, France
| | - D Salmon
- Pharmacie, groupement hospitalier Édouard-Herriot, plateforme Fripharm, 5, place d'Arsonval, 69437 Lyon cedex 03, France; Laboratoire de recherche et développement de pharmacie galénique industrielle, faculté de pharmacie, EA 4169 « fonctions physiologiques et pathologiques de la barrière cutanée », université Claude-Bernard Lyon 1, 8, avenue Rockefeller, 69373 Lyon cedex 08, France
| | - L Gabert
- Centre de recherche en nutrition humaine, Rhône Alpes, centre européen nutrition santé, groupement hospitalier Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France
| | - G Nugue
- Centre de recherche biomédicale Edmond-J.-Safra, 17, rue des Martyrs, 38054 Grenoble cedex 9, France; Institut de recherche biomédicale des armées, BP 73, 91223 Brétigny/Orge cedex, France
| | - C Sandre-Balester
- Centre de recherche biomédicale Edmond-J.-Safra, 17, rue des Martyrs, 38054 Grenoble cedex 9, France; Centre hospitalier universitaire de Grenoble, CS 10217, 38043 Grenoble cedex 9, France
| | - F Berger
- Centre de recherche biomédicale Edmond-J.-Safra, 17, rue des Martyrs, 38054 Grenoble cedex 9, France; Centre hospitalier universitaire de Grenoble, CS 10217, 38043 Grenoble cedex 9, France
| | - F Pirot
- Pharmacie, groupement hospitalier Édouard-Herriot, plateforme Fripharm, 5, place d'Arsonval, 69437 Lyon cedex 03, France; Laboratoire de recherche et développement de pharmacie galénique industrielle, faculté de pharmacie, EA 4169 « fonctions physiologiques et pathologiques de la barrière cutanée », université Claude-Bernard Lyon 1, 8, avenue Rockefeller, 69373 Lyon cedex 08, France
| | - C Pivot
- Pharmacie, groupement hospitalier Édouard-Herriot, plateforme Fripharm, 5, place d'Arsonval, 69437 Lyon cedex 03, France
| |
Collapse
|